News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
News Kaken details the data behind its PI3K inhibitor filing Kaken has revealed the data that supported its recent marketing application for serabelisib as a treatment for vascular malformations in Japan.
News Precision Neuro breaks new ground in BCI technology Precision Neuroscience has shown that people can control electronic devices with thought alone, without a need for electrodes implanted in the brain.
News Gilead, MSD share data on once-weekly oral HIV treatment Gilead/MSD's once-weekly oral medicine for HIV has been shown to achieve high rates of viral suppression in phase 3, setting up regulatory filings.
News Trump sets course for 100%, then 200%, tariffs on generics Trump has said he intends to impose tariffs of 100% on generic drugs imported into the US from 2028, rising to 200% after a year, in a reshoring push.
News Novo sues Lilly over 'misleading' GLP-1 ad campaigning The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.